No Data
Some biomedical stocks rise, Akeso (09926) rises 13.9%, institutions indicate that the sector's fundamentals are gradually bottoming out and stabilizing.
Golden Finance News | Some biomedical stocks rose, with Akeso (09926) up 13.9%, Sanpower Medical (02257) up 5.47%, China Antibody (03681) up 4.35%, GL Pharm (01672) up 4.12%, Viva Biotech (01873) up 3.45%, Wuxi AppTec (02359) up 2.6%, Wuxi Bio (02269) up 1.27%. China Post Securities expressed that the overall revenue growth rate of the biomedical sector compared to the same period last year is -1.26%, lower than Q1 growth rate, mainly due to vaccines (-32.75%), and CXO (-9.45%).
Geely Pharmaceutical - B (01672) rose 2.06%, now trading at 0.990 yuan.
As of 11:45, Goldenmed Pharmaceutical - B (01672) rose 2.06% from the previous closing price to 0.990 yuan; the trading volume was 4.4431 million shares, with a transaction value of 4.3879 million Hong Kong dollars.
Gale Pharmaceutical-B (01672.HK) spent 0.3312 million Hong Kong dollars to repurchase 0.345 million shares on September 5th.
Galepharmaceutical-B (01672.HK) announced on September 5th that it will repurchase 0.345 million shares at a cost of 0.3312 million Hong Kong dollars on September 5, 2024, at a repurchase price of 0.96 Hong Kong dollars per share.
GeLi Pharmaceutical-B (01672.HK) increased its mid-term R&D expenses by 43.5% to 0.132 billion yuan.
Geely Pharmaceuticals-B (01672.HK) announced that the group's research and development expenses increased by 43.5% to approximately RMB 132.4 million for the six months ended June 30, 2024. The group's loss for the period increased by 687.0% to approximately RMB 130.3 million, mainly due to an increase in research and development costs compared to the same period last year.
Express News | Ascletis Pharma H1 Revenue RMB 49 Million
Express News | Ascletis Pharma H1 Net Income RMB -130.3 Million
No Data
No Data
